These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12568221)

  • 1. Indirect hyperbilirubinemia with indinavir.
    Satija P; Parikh F; Aggarwal V; Sharma B; Hakim A; Pai-Dhungat JV
    J Assoc Physicians India; 2002 Oct; 50():1316-7. PubMed ID: 12568221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
    Hirsch MS; Steigbigel RT; Staszewski S; McMahon D; Fischl MA; Hirschel B; Squires K; DiNubile MJ; Harvey CM; Chen J; Leavitt RY;
    Clin Infect Dis; 2003 Oct; 37(8):1119-24. PubMed ID: 14523778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-exposure prophylaxis.
    van der Ende ME; Regez RM; Schreij G; van der Meer JT; Danner SA;
    Int J STD AIDS; 2002 Dec; 13 Suppl 2():30-4. PubMed ID: 12537723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buffalo hump: what the experts suggest.
    Piliero PJ; McComsey GA
    AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
    Coplan PM; Cook JR; Carides GW; Heyse JF; Wu AW; Hammer SM; Nguyen BY; Meibohm AR; DiNubile MJ;
    Clin Infect Dis; 2004 Aug; 39(3):426-33. PubMed ID: 15307012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir.
    Nouts C; Bonarek M; Morlat P; Delevaux I; Bonnet F; Lacoste D; Bernard N; Beylot J
    Int J STD AIDS; 2001 Jan; 12(1):29-33. PubMed ID: 11177479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
    Nerad JL; Kessler HA
    Clin Infect Dis; 2001 Jun; 32(11):1635-6. PubMed ID: 11340537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of the protease inhibitor indinavir in children with HIV infection.
    Mueller BU; Sleasman J; Nelson RP; Smith S; Deutsch PJ; Ju W; Steinberg SM; Balis FM; Jarosinski PF; Brouwers P; Mistry G; Winchell G; Zwerski S; Sei S; Wood LV; Zeichner S; Pizzo PA
    Pediatrics; 1998 Jul; 102(1 Pt 1):101-9. PubMed ID: 9651421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis.
    Woolley I; Tapley N; Korman TM
    AIDS; 2003 Jul; 17(11):1709. PubMed ID: 12853759
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-HIV agents. Indinavir--3 years and still going strong.
    TreatmentUpdate; 2000 Sep; 12(6):3-4. PubMed ID: 12132460
    [No Abstract]   [Full Text] [Related]  

  • 11. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
    Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
    Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New recommendations on health care worker exposure to HIV.
    Woodward J
    STEP Perspect; 1996; 8(3):8-10. PubMed ID: 11364268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and side-effects of post-exposure prophylaxis for HIV infection.
    Parkin JM; Murphy M; Anderson J; El-Gadi S; Forster G; Pinching AJ
    Lancet; 2000 Feb; 355(9205):722-3. PubMed ID: 10703807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Crystalluria and nephrolithiasis during therapy with the protease inhibitor indinavir].
    Rickerts V; Kober A; Stille W
    Dtsch Med Wochenschr; 1997 Jun; 122(24):803. PubMed ID: 9229567
    [No Abstract]   [Full Text] [Related]  

  • 15. Indinavir--effect on sugar and insulin.
    TreatmentUpdate; 2001 Jun; 13(2):7-8. PubMed ID: 11570290
    [No Abstract]   [Full Text] [Related]  

  • 16. Indinavir, zidovudine, lamivudine: 3-year follow-up.
    Dworkin MS; Wan PT
    Ann Intern Med; 2001 Jan; 134(2):165. PubMed ID: 11177322
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evidence-based therapeutic drug monitoring for indinavir].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):239-46. PubMed ID: 21819808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor.
    Carr A; Brown D; Cooper DA
    AIDS; 1997 Nov; 11(13):1657-8. PubMed ID: 9365776
    [No Abstract]   [Full Text] [Related]  

  • 20. Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity.
    Trainor LD; Steinberg JP; Austin GW; Solomon HM
    Arch Pathol Lab Med; 1998 Mar; 122(3):256-9. PubMed ID: 9823864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.